@article {7431,
	title = {High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma},
	journal = {Blood Cancer Journal},
	volume = {6},
	year = {2016},
	note = {Export Date: 21 February 2017},
	month = {2016},
	pages = {e482},
	abstract = {Periostin is an extracellular matrix protein that is implicated in the biology of normal bone remodeling and in different cancer cell growth and metastasis. However, there is no information on the role of periostin in multiple myeloma (MM). Thus, we evaluated periostin in six myeloma cell lines in vitro; in the bone marrow plasma and serum of 105 newly diagnosed symptomatic MM (NDMM) patients and in the serum of 23 monoclonal gammopathy of undetermined significance (MGUS), 33 smoldering MM (SMM) patients, 30 patients at the plateau phase post-first-line therapy, 30 patients at first relapse and 30 healthy controls. We found high levels of periostin in the supernatants of myeloma cell lines compared with ovarian cancer cell lines that were not influenced by the incubation with the stromal cell line HS5. In NDMM patients the bone marrow plasma periostin was almost fourfold higher compared with the serum levels of periostin and correlated with the presence of fractures and of diffuse magnetic resonance imaging pattern of marrow infiltration. Serum periostin was elevated in NDMM patients compared with healthy controls, MGUS and SMM patients and correlated with advanced disease stage, high lactate dehydrogenase, increased activin-A, increased bone resorption and reduced bone formation. Patients at first relapse had also elevated periostin compared with healthy controls, MGUS and SMM patients, while even patients at the plateau phase had elevated serum periostin compared with healthy controls. These results support an important role of periostin in the biology of myeloma and reveal periostin as a possible target for the development of antimyeloma drugs. {\textcopyright} 2016 The Author(s).},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84990869075\&doi=10.1038\%2fbcj.2016.90\&partnerID=40\&md5=2cdc4f1c52163b7bf504f6d9e2f9185d},
	author = {Terpos, E. and Christoulas, D. and Kastritis, E. and Bagratuni, T. and Gavriatopoulou, M. and Roussou, M. and Papatheodorou, A. and Eleutherakis-Papaiakovou, E. and Kanellias, N. and Liakou, C. and Panagiotidis, I. and Migkou, M. and Kokkoris, P. and Moulopoulos, L.A. and Dimopoulos, M.A.}
}
